Indian pharma industry's big pivot: Report reveals sector transitioning from generics to innovation
This paradigm shift is illuminated in the recently published 2023 Convention on Pharmaceutical Ingredients (CPHI) annual report.
Stay updated with breaking news from Pharma Index. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This paradigm shift is illuminated in the recently published 2023 Convention on Pharmaceutical Ingredients (CPHI) annual report.
Overall, the index has still been in the range with 19,750-19,800 likely to act as a crucial resistance as breaking of the same can drive the Nifty50 towards 20,000 mark, whereas 19,500 is expected to be immediate support and 19,200 may be crucial support for the index, experts said
Despite the broader market's resilience, the pharmaceutical sector exhibits a strong bearish sentiment, characterised by short positions in Glenmark, Cipla, Alkem, and Dr Reddy's
The next targets for the Nifty50 to watch out for would be 20,500-21,000 in the short term, considering the strong momentum sustained through the last seven sessions with participation from bank and IT stocks
It is the time to increase the exposure in largecaps and reduce in midcaps. Risk reward does not seem favourable in mid and smallcaps.